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Background: Human BiP is traditionally regarded as a major endoplasmic reticulum (ER) chaperone performing a
number of well-described functions in the ER. In recent years it was well established that this molecule can also be
located in other cell organelles and compartments, on the cell surface or be secreted. Also novel functions were
assigned to this protein. Importantly, BiP protein appears to be involved in cancer and rheumatoid arthritis progression,
autoimmune inflammation and tissue damage, and thus could potentially be used for therapeutic purposes. In
addition, a growing body of evidence indicates BiP as a new therapeutic target for the treatment of neurodegenerative
diseases. Increasing importance of this protein and its involvement in critical human diseases demands new source of
high quality native recombinant human BiP for further studies and potential application. Here we introduce yeast
Saccharomyces cerevisiae as a host for the generation of human BiP protein.
Results: Expression of a full-length human BiP precursor in S. cerevisiae resulted in a high-level secretion of mature
recombinant protein into the culture medium. The newly discovered ability of the yeast cells to recognize, correctly
process the native signal sequence of human BiP and secrete this protein into the growth media allowed simple
one-step purification of highly pure recombinant BiP protein with yields reaching 10 mg/L. Data presented in this
study shows that secreted recombinant human BiP possesses native amino acid sequence and structural integrity, is
biologically active and without yeast-derived modifications. Strikingly, ATPase activity of yeast-derived human BiP
protein exceeded the activity of E. coli-derived recombinant human BiP by a 3-fold.
Conclusions: S. cerevisiae is able to correctly process and secrete human BiP protein. Consequently, resulting
recombinant BiP protein corresponds accurately to native analogue. The ability to produce large quantities of
native recombinant human BiP in yeast expression system should accelerate the analysis and application of this
important protein.Background
Human BiP (immunoglobulin heavy chain-binding pro-
tein), also known as GRP78, is an essential ER resident
Hsp70 family chaperone [1]. Its functions in the ER are
thoroughly studied and well described (reviewed in [2]).
BiP is a major chaperone and most abundant protein in
the ER, it plays a role in protein transport into the ER,
folding, assembly, export and degradation, signal trans-
duction and calcium homeostasis. Therefore, BiP is a
central regulator of ER homeostasis and essential for
embryonic cell growth and pluripotent cell survival [3].
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stated.more attention due to its newly discovered functions,
localization in the cell, involvement in important human
diseases and potential therapeutic applications. Recently
it was recognized that in specific cell types or when sub-
jected to stress, BiP can be located in cell compartments
outside the ER, including the cell surface, the cytoplasm,
the mitochondria and the nucleus. Also secretion into
the extracellular space, where it affects the cell growth
and signalling, was observed (reviewed in [4]).
Particularly intriguing is BiP involvement in progression
of critical human diseases, such as cancer and neurode-
generative disorders. Current studies have established that
BiP plays crucial and pleiotropic role in cancer progres-
sion (reviewed in [3,5]). It is overexpressed and translo-
cated onto the cell surface in most cancer cells, where it
regulates cell survival and proliferation, tumor progressiontd. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Yeast vector pFDC-BiP for the expression of human BiP.
pFDC vector contains one inducible expression cassette under control
of Saccharomyces cerevisiae GAL7 promoter with corresponding
transcription terminator and the other cassette under control of
constitutive S. cerevisiae promoter PGK1 with corresponding transcription
terminator. 2 μm DNA, 1.74 kb fragment of yeast 2 μm DNA. PGK1-P,
PGK1 gene promoter ( − 1 to - 541 bp); PGK1-T, PGK1 gene transcription
terminator (371 bp). GAL7-P, GAL7 gene promoter ( − 1 to - 716 nt);
GAL7-T, GAL7 gene transcription terminator (381 bp); FDH1, FDH1 gene
of Candida maltosa, conferring resistance to formaldehyde; bla – beta
lactamase gene, conferring resistance to ampicillin; BiP – human BiP
protein coding gene (HSPA5, GenBank: AF216292).
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adverse hypoxic and nutrient-deprived microenvironment.
Naturally, targeting BiP sensitizes cancer cells to therapy
[6]. Furthermore, preferential expression of BiP on the
surface of tumor cells but not in normal organs suggests
that surface BiP can serve both as a target as well as a
mediator for cancer-specific therapy [7]. Recently BiP was
suggested as a therapeutic target for neurodegenerative
disorders (reviewed in [8]). Most neurodegenerative disor-
ders are characterized by activation of the UPR and
altered expression and activity of BiP in ageing cells,
raising the question whether the lack of BiP could be a
predisposing factor for many neurodegenerative disorders.
In some cases endogenous overexpression of BiP was
shown to have anti-apoptotic and neuroprotective effects
in mice and rat models [9-11]. Taking together, these
discoveries change the paradigm on BiP functions and sug-
gest novel therapeutic approaches targeting this protein.
For further research and studies of the potential appli-
cation of this protein, high quality and widely affordable
recombinant human BiP protein is needed. Currently,
Escherichia coli is the host of choice for the production
of recombinant human BiP protein using various purifi-
cation techniques [12-16], but resulting protein is less
active than native analogue [16] and yields are low
[16,17]. To the best of our knowledge, this work is the
first to report yeast Saccharomyces cerevisiae as a host
for the generation of human BiP protein. In our previous
study, we inserted different human ER chaperones into
the yeast to facilitate impaired maturation of recombin-
ant Measles virus hemagglutinin [18,19]. Even though
considerable amount of recombinant human BiP was
found to be localized in the yeast ER, subsequent studies
revealed that the protein was also secreted outside the
yeast cell, similarly to another human ER chaperone
ERp57 [20]. Here we report how this discovery allows
simple and cost-effective purification of large amounts
of active human BiP. Our studies revealed that the secre-
tion of human BiP chaperone by yeast cells is mediated
by correctly processed native signal sequence of BiP
protein. Analysis of the yeast-derived human BiP showed
that this protein highly resembles its native analogue.
ATPase assay demonstrated that yeast-secreted recom-
binant protein is 3-fold more active when compared to
recombinant BiP purified from E. coli. In conclusion,
yeast S. cerevisiae is an excellent host for the production
of native recombinant BiP protein.
Results and discussion
Expression and purification of human BiP protein
Protein expression was carried out in S. cerevisiae trans-
formants harboring multicopy autonomously replicating
plasmid pFDC-BiP (Figure 1). In this study, we expressed
the entire native amino acid sequence of human BiPprecursor without any changes (i.e. yeast secretion signals
and tags were not used). Yeast cells synthesized exactly
the same polypeptide sequence as in human cells. There-
fore, generated protein product can be considered as
“native recombinant”. Surprisingly, recombinant human
chaperone was not only found in membrane protein
fractions of the yeast cells, as previously described [18],
but was also found in fairly large amount in the growth
medium (Figure 2). Secreted recombinant BiP protein was
purified from the culture medium up to 95% purity as
described in Methods (Figure 3). According to data
obtained from densitometric analysis of SDS–PAGE gels,
secreted human BiP protein constitutes for approx. 35-40%
of all yeast secreted proteins (Figure 3 lane A), subsequent
microfiltration increases its purity to approx. 50% (Figure 3
lane B) and one-step affinity chromatography using ATP-
agarose is enough to reach 95% purity (Figure 3 lane D).
Yields obtained were approx. 9–10 mg from 1 L culture
medium with purification efficiency reaching up to 60%. It
is a high yield compared to the production of this protein
in bacterial expression system. Similar amount of recom-
binant mouse BiP was purified from 20 L of E.coli culture
[17]. Purification of secreted human BiP was not as effi-
cient as that of yeast-secreted human ERp57 protein [20],
because BiP protein seems to bind to polyethersulfone
membrane of tangential ultrafiltration cassettes. This is
Figure 3 Purification of secreted recombinant human BiP
protein from yeast culture medium. M – unstained protein ladder
(ThermoScientific, cat. no. 26614). A – crude yeast growth medium
(20× concentrated), B – yeast growth medium after microfiltration
(20× concentrated), C – 20× concentrated proteins from yeast
growth medium in binding buffer after tangential ultrafiltration;
D – purified yeast-derived recombinant human BiP protein (5 μg).
Figure 2 Secretion of human BiP protein into the yeast growth
medium. SDS-PAGE (A) and Western blot against human BiP protein
(B) of crude growth medium (40× concentrated) of yeast cells carrying
control vector pFDC or pFDC-BiP for expression of human BiP. Cells
were incubated for 36 h in YEPD medium. M – prestained molecular
ladder (ThermoScientific, cat. no. 26618).
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centration by tangential ultrafiltration, where BiP consti-
tutes to approx. 25% of total proteins (Figure 3 lane C).
Despite this, secretion of human BiP into the yeast
growth medium allows simple and cost-effective gen-
eration of native recombinant protein, which can be
further optimized.
Molecular weight, processing and oligomerization of
recombinant human BiP protein
The band of purified secreted BiP protein was excised
from SDS-PAA gel and identified by trypsin digestion
and MALDI-TOF/TOF tandemic MS/MS (mass spec-
trometry) together with UPLC/MSE method using a
service of the Proteomics Centre at the Institute of
Biochemistry (Vilnius, Lithuania). Tryptic peptide mass
fingerprinting confirmed that purified secreted protein
represents human BiP, which was identified by both
methods with a high level of confidence and ~57% se-
quence coverage (Figure 4). Figure 4 shows identified
peptides (indicated in bold) of human BiP (Swiss-Prot:
P11021). We were not able to identify N-terminal tryptic
peptide by this method. However, search in a Swiss-Prot
Protein Database using PLGS (Protein Lynx Global
Service) search engine in UPLC/MSE method identified a
C-terminal human GRP78/BiP peptide (Y)GSAGPPPT
GEEDTAEKDEL(−), which is underlined in Figure 4. This
demonstrates that yeast-secreted human BiP protein
possesses intact C-terminal amino acid sequence inclu-
ding KDEL ER retention/retrieval signal. Furthermore,
N-terminal sequencing by Edman degradation confirmed
that the first five N-terminal amino acids of the recom-
binant protein are NH2-EEEDK (Figure 5), which corre-
sponds to the N-terminal sequence of mature human BiP
protein after signal cleavage [21].
The molecular mass of S. cerevisiae-secreted BiP pro-
tein was measured by electrospray mass spectrometry
(ESI-MS) using Agilent Q-TOF 6520 mass spectrometer.
ESI-MS of a whole S. cerevisiae-derived recombinant
BiP protein molecule showed a molecular mass of
70478.39 Da, which exactly corresponds to theoretically
predicted mass of mature human BiP (19–654 aa) poly-
peptide (Figure 5). It indicates that secreted recombinant
BiP has no yeast-derived modifications, including phos-
phorylation and ADP-ribosylation. In mammalian cells
free BiP can be reversibly phosphorylated and ADP-
ribosylated. Such modifications lead to reversible aggrega-
tion and subsequent inactivation of BiP protein [22-26].
Therefore, BiP exists in mammalian cells as an active
monomer, less active or inactive dimer, or in inactive olig-
omeric form [16,17,25]. To determine the oligomerization
of the yeast-secreted human BiP, we analyzed it by
native PAGE as described in Methods. As it was ex-
pected, unmodified yeast-secreted human BiP was present
Figure 4 Peptide mass fingerprinting of S. cerevisiae secreted GRP78/BiP protein by MALDI-TOF/TOF tandemic MS/MS together with
UPLC/MSE method.
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applications, yeast-secreted recombinant protein might
be even preferable over native protein, because majority
of the recombinant BiP protein is in active (see below)
monomeric form compared to diverse oligomerization of
the native mammalian BiP protein.
Taken together, our data indicates that yeast-secreted
recombinant human BiP exactly corresponds to the ac-
tive monomeric form of native mature human BiP pro-
tein. It is correctly processed and does not carry any
modifications or additional amino acid residues as it isFigure 5 ESI-MS of recombinant human BiP purified from S. cerevisiaeoften the case when using S. cerevisiae prepro α mating
factor signal sequence for the secretion of recombinant
proteins, because of the inefficient cleavage of Ste13
peptidase [27]. It also suggests that translocon machin-
ery and signal peptide peptidase complex of yeast and
human cells are compatible, because native signal se-
quence of human BiP protein is recognized and correctly
cleaved in yeast cells. This allows translocation of re-
combinant protein into the ER followed by unexpected
secretion outside the yeast cells. Secretion of human BiP
protein by yeast is an interesting phenomenon, especially.
Figure 6 Native PAGE of recombinant human BiP. 5 μg of purified
recombinant human BiP was loaded on gel. BSA was loaded as
molecular weight marker.
Figure 7 Partial proteolysis of recombinant BiP with proteinase
K in the presence of nucleotides. M – prestained protein ladder
(ThermoScientific, cat. no. 26616). Undigested recombinant BiP (A), or
digested with proteinase K without nucleotides (B), in the presence
of 100 μM ATP (C) or 100 μM ADP (D).
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a signal for translocation of protein into the ER, but not
as a secretion signal. This finding not only allows simple
generation of native human BiP protein in yeast cells,
but also might serve as a convenient model to study
mechanism of protein retention in the ER. As we repor-
ted earlier [20], human ERp57 protein is also secreted by
yeast cells with the intact ER retention signal. Replacing
ER retention signals of both BiP and ERp57 to yeast
preferable ER retention signal HDEL [28] did not sup-
press the secretion of those proteins (our unpublished
data). Also, overload of the yeast ER retrieval machinery
as the reason for secretion of human ERp57 and BiP
proteins can be omitted, because overexpression of yeast
Kar2 protein with native HDEL ER retrieval sequence
using the same pFDC vector did not lead to the secre-
tion of this protein (Additional file 1: data 1). These
results indicate that the retention of ER luminal proteins
is complicated and still unsolved mechanism, which does
not strictly depend only on HDEL/KDEL sequences, but
is likely a combination of several factors. Observed
secretion of human ER luminal proteins ERp57 and BiP
by yeast cells can serve as a more convenient model to
study this fundamental issue than the full genome-wide
screening of yeast Kar2p secretion mutants [29].
Conformation of yeast-secreted human BiP
To assess the quality of yeast-derived human BiP pro-
tein, folding state and activity were determined. Correctfolding was evaluated by partial proteolysis of recombin-
ant human BiP protein. Partial protease digestion is
often used as a measure of the structural integrity of BiP
protein, because HSP70 proteins produce very distinct-
ive proteolytic patterns when digested in the presence of
nucleotides. ATP protects 60- and 44-kDa fragments
from digestion, whereas ADP protects only the 44-kDa
fragment [14,30]. S. cerevisiae-secreted human BiP pro-
tein was digested with proteinase K in the presence of
ATP or ADP and analyzed by SDS-PAGE as described in
Methods (Figure 7). Yeast derived human BiP protein
bound ATP, and this protected a ~60 kDa fragment
from proteolysis by proteinase K (Figure 7 lane C),
whereas binding of ADP protected slightly larger amount
of ~44 kDa fragment compared to the samples without
added nucleotides or with added ATP (Figure 7 lane D
compared to lanes B and C). Similar data was previously
used to demonstrate correct folding of both native
canine [30] and E. coli-expressed recombinant human
BiP proteins [14].
ATP-ase activity of yeast-derived human BiP protein
ATPase activity of yeast-expressed human BiP protein
was measured and compared with commercially avail-
able E. coli-derived human BiP using non-radioactive
ATPase assay as described in Methods. This test is com-
monly used to assess activity of the BiP protein [12,31].
As it is evident in Figure 8, both proteins exhibited
ATPase activity, but amount of liberated phosphate
(μM/hr/μg protein) by yeast-derived BiP was 3-fold
larger than that of bacteria-derived protein (~6.3 μM
compared to ~2.1 μM) showing a 3-fold higher activity
of the yeast-derived protein. The amount of phosphate
liberated by E. coli-produced recombinant BiP in our
Figure 8 ATPase activity of yeast-secreted human BiP. The
amount of released phosphate by 1 μg of either bacterial or
yeast-derived human BiP was determined after incubation at 25°C
for 75 min. with a non-radioactive procedure. Values are the mean
of three separate experiments with an error bar representing SD.
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turer, validating our results. Such difference in activity
between yeast- and bacteria-derived BiP proteins may be
explained by the fact that yeast-secreted human BiP
undergoes protein quality control throughout the yeastFigure 9 Evaluation of amount of intracellular human BiP protein in y
indicated amounts of purified BiP; (B) Western blot using polyclonal antibodie
cat. no. 26618). pFDC and pFDC-hBiP – crude lysates (10 μg of whole cell pro
pFDC-hBiP plasmid, respectively. 50, 75, 100, 150, 200, 300, 400 – amounts insecretion pathway, which allows secretion of only cor-
rectly folded proteins. Meanwhile, E. coli does not have
the ER, and the synthesis of recombinant human BiP is
performed in different intracellular environment that
may be less suitable for the proper maturation of the
protein. Similar ratio of ATPase activity comparing
native and E. coli-derived recombinant BiP protein was
observed earlier [16], where recombinant hamster BiP
protein showed only 30% activity of the native bovine
liver BiP. Also, as we reported earlier [20], the yeast-
secreted human ERp57 protein catalyzed the reduction
of insulin in faster rate than recombinant human ERp57
from E. coli. Evidently higher activity of S. cerevisiae-se-
creted human BiP and ERp57 proteins compared to
E. coli-derived recombinant analogues demonstrates
that yeast is superior host for the production of BiP
and other human ER chaperones.
Secretion efficiency of human BiP in yeast
As it was mentioned, human BiP protein was expressed
previously in S. cerevisiae and was found inside the cell
[18]. Here we have shown that this protein is also
secreted. To evaluate the efficiency of secretion of
human BiP protein driven by its native signal sequence,
we compared amounts of intracellular and secreted BiP
protein. SDS–PAGE analysis of crude lysates harbouring
pFDC-BiP plasmid revealed clear additional band of
recombinant human BiP compared to control cells carry-
ing pFDC vector (Figure 9A, lanes pFDC and pFDC-hBiP).
Also, quantitative Western blot using antibodies againsteast S. cerevisiae cells. (A) SDS–PAGE of crude yeast lysates and
s against human BiP. M – prestained protein ladder (ThermoScientific,
tein in each lane) of yeast cells transformed with pFDC vector and
nanograms of purified secreted human BiP protein loaded on gel.
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metric analysis of both SDS-PAGE gel and Western blot
showed that intracellular BiP constituted for approx. 0.9%
of total cell protein. Evaluation of amount of proteins
according to cell biomass produced from 1 L of culture
revealed that approx. 70% of BiP was expressed internally
(approx. 35 mg) and 30% was secreted into the culture
medium (approx. 15 mg). Thus, secretion efficiency of
human BiP protein in yeast S. cerevisiae cells is slightly
higher than that of human ERp57 protein we reported
earlier [20].
Potential applicability of the results
This study revealed a new potential of the yeast to
efficiently produce native recombinant human ER
chaperones in the secreted form. It should be noted
that a high-level secretion of these proteins by using
their native signal sequences in yeast expression sys-
tem is quite unusual. It is known that some secreted
human proteins may be secreted by yeast cells using na-
tive secretion signal sequences [32,33], with a very few ex-
amples of a high-level secretion as in the case of human
serum albumin in P. pastoris [33]. However, it may be ex-
pected that secreted human proteins will also be secreted
in yeast cells using the same signal sequence. In contrast,
the secretion of intracellular human proteins, such as ER-
resident chaperones, is not expected when expressed in
yeast. Moreover, the secretion level of human ER chaper-
ones in yeast is unexpectedly high and allows efficient
production of correctly processed recombinant products.
As it was mentioned, in some cases the native human BiP
was shown to be directed to the cell surface or secreted
outside the cell where it is involved in a multitude of
biological processes [4]. Possible therapeutic applications
of BiP are mostly related to the extracellular protein form.
For example, BiP is considered as a therapeutic agent of
the third generation of biologics for immunological dis-
eases such as rheumatoid arthritis [34]. It was shown that
intravenously injected recombinant BiP is able to suppress
arthritis and tissue inflammation in mice [35,36]. Yeast-
secreted recombinant protein may be advantageous in such
applications, because it is generated in the same way as the
native extracellular BiP and corresponds to the native ana-
log insofar as possible. Furthermore, yeast-derived heterol-
ogous proteins are free of toxic contaminations and are
excellent tools for developing biopharmaceuticals, because
S. cerevisiae is acknowledged as GRAS (generally regarded
as safe) organism. Therefore, secretory expression of native
recombinant human BiP in yeast could be exploited for
efficient and safe production of potential therapeutic agent.
Conclusions
Here we introduce the yeast S. cerevisiae as an excellent
host for the generation of active human BiP protein. Inthis study we present evidence that yeast holds several
key advantages over E. coli cells currently used for the
synthesis of recombinant BiP protein: (a) newly discov-
ered ability of yeast cells to recognize and process the
native signal sequence of human BiP and their inability
to retain it in the ER leads to secretion of this protein;
(b) secretion of the protein allows simple and cost-
effective one-step purification; (c) yeast-secreted human
BiP exactly corresponds to the native protein; (d) yeast-
derived human BiP is correctly folded and three-fold
more active than recombinant BiP produced in E. coli.
Considering the fact that growing amount of data associ-
ates BiP protein with critical human diseases and indi-
cates this protein as a potential therapeutic target or
agent, the ability of yeast cells to produce large amounts
of native recombinant BiP protein might be invaluable.
Also, secretion of this ER luminal human protein by
yeast cells might serve as a convenient model to study
retention of ER luminal proteins in the ER in general.
Methods
Construction of yeast vector for expression of human BiP
All DNA manipulations were performed according to
standard procedures [37]. Recombinant plasmids were
amplified in E. coli DH5αF’ cells. Human BiP coding gene
(HSPA5, GenBank:AF216292) was cloned under the con-
trol of constitutive yeast PGK1 gene promoter in pFDC
vector, yielding pFDC-BiP plasmid (Figure 1), as it was
described previously [18]. Briefly, cDNA encoding full-
length human BiP protein precursor was amplified from
commercial human adult liver cDNA library (Clontech)
by PCR using specific oligonucleotide primers, digested
with restriction endonuclease XbaI and cloned into yeast
expression vector pFDC. Cloned HSPA5 gene sequence
was verified by DNA sequencing and generated plasmid
pFDC-BiP was used for the transformation of yeast
S. cerevisiae cells.
Yeast strain, medium, transformation and cultivation
S. cerevisiae strain AH22 MATa leu2 his4 was used for
expression experiments. Transformation of S. cerevisiae
cells was performed by conventional LiCl method [37].
The selection of transformants resistant to formaldehyde
was carried out on YEPD (yeast extract 1%, peptone 2%,
dextrose 2%) agar supplemented with 4 mM formalde-
hyde. S. cerevisiae transformants were grown in YEPD
medium supplemented with 4 mM formaldehyde.
Protein expression and purification
Yeast cells carrying human HSPA5 gene were grown for
36 h in YEPD medium. Cells were separated from the
medium by centrifugation at 2000 g for 10 min. Yeast
growth medium was further prefiltered through qualitative
filter paper (VWR, cat. No. 516–0812) with subsequent
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1.6 μM (SartoriusStedim Biotech, cat. no. FT-3-1101-047),
0.45 μM (SartoriusStedim Biotech, cat. no. 15406–47) and
0.2 μM (SartoriusStedim Biotech, cat.n o. 15407-47-MIN).
After microfiltration, proteins were concentrated and
transferred into the binding buffer (20 mM HEPES,
50 mM NaCl, 10 mM MgCl2, pH 8.0) through tangential
ultrafiltration using cassettes with 50 kDa cut-off mem-
branes (SartoriusStedim Biotech, cat. no.VF20P3). Further,
proteins were mixed with 6-AH-ATP-Agarose (Jena
Bioscience, cat. no. AC-129 L) equilibrated in the same
buffer and incubated for 2–3 hours at 4°C in batch format.
Unbound proteins were removed by washing the resin
with 20 column volumes of binding buffer while bound
proteins were eluted with equal column volume of elution
buffer (20 mM HEPES, 50 mM NaCl, 10 mM MgCl2,
5 mM ATP, pH 7.5). Elution fractions were analyzed
by SDS-PAGE. Three subsequent elution fractions
showed ~ 95% pure human GRP78/BiP protein. These
fractions were pooled and dialysed against ATPase
buffer (50 mM HEPES, 50 mM NaCl, 2 mM MgCl2,
pH 6.8).
Preparation of crude yeast lysates, SDS-PAGE and
Western blotting were performed exactly as described
previously [18].
Partial proteolysis of recombinant BiP in the presence of
nucleotides
Partial proteolysis of yeast derived human BiP with
proteinase K was performed as described by Wei and
Hendershot [14]. 65-μl reactions were assembled that
contained 10 μg of recombinant BiP, 2 μg of protein-
ase K (or similar volume of buffer for control), and
100 μM ATP or ADP in the ATPase buffer (50 mM
HEPES, 50 mM NaCl, 2 mM MgCl2, pH 6.8). After
incubation at 37°C for 25 min., the reaction was
stopped by adding 10 μl of 1 mg/ml phenylmethylsul-
fonylfluoride and incubating it on ice for 30 min. The
digested recombinant BiP was then analyzed by SDS-
PAGE.
ATPase assay
Non-radioactive ATPase assay was performed as de-
scribed previously [12]. Reactions were performed in
50 μl volumes as follows: 1 μg of recombinant BiP
protein (or equal volume of buffer for negative control)
with 20 mM KCl and 20 μM ATP in ATPase buffer
(50 mM HEPES, pH 6.8, 50 mM NaCl, 2 mM MgCl2) was
incubated at 25°C for 75 min. Concentration of the
phospate liberated from ATP was measured by spec-
trofotometer (TECAN Infinite 200, wave length 620 nm)
using Malachite Green Phosphate Assay Kit (Cayman
Chemical, cat. no. 10009325) according to manufacturers’
recommendations.Native PAGE
Purified recombinant BiP was mixed in equal volumes
with sample buffer (0.01% Bromophenol Blue and 20%
glycerol in TBE buffer (90 mM Tris, 90 mM Boric acid,
2 mM EDTA, pH 8)) and loaded onto 10% polyacryl-
amide gels. Gels were run in TBE buffer in 4°C at 100 V
and 30 mA for 8–10 hours. After electrophoresis gels
were stained with Coomassie brilliant blue R-250.
Other methods and materials
N terminus sequencing of yeast secreted human BiP
protein by Edman degradation was performed by
AltaBioscience.
The molecular mass of protein was measured by
electrospray mass spectrometry using Agilent Q-TOF
6520 mass spectrometer.
Protein concentrations were determined by Roti-Nano-
quant Protein-assay (Carl Roth Gmbh., cat. no. K880).
Densitometric analysis of SDS-PAGE gels and Western
blots, scanned with ImageSanner III (GE Healthcare)
was performed with ImageQuant TL (GE Healthcare)
software using default settings.
Precipitation of proteins from yeast growth medium
for SDS-PAGE analysis was performed based on a de-
fined methanol-chloroform-water mixture, as described
earlier [38].
Recombinant human BiP protein purified from E.
coli was purchased from StressMarq Biosciences Inc.
(cat. no. SPR-107A).
Rabbit polyclonal antibodies against human BiP protein
were purchased from Abcam (cat. no. ab21685).
Additional file
Additional file 1: Concentrated culture medium of yeast cells
over-expressing human BiP and Kar2 proteins. M – prestained
protein ladder (ThermoScientific, cat. no. 26616). 40× concentrated yeast
growth medium of yeast cells harbouring control vector pFDC, vector
pFDC-BiP for over-expression of human BiP and pFDC-KAR2 for
over-expression of yeast Kar2 protein.
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